Chugai Announces 2026 2nd Quarter Results

TOKYO, July 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the second quarter of fiscal year 2026.

• Core revenue of ¥663.3 billion (+14.7%), core operating profit of ¥329.1 billion (+21.0%), and core net income of ¥238.4 billion (+23.2%) were achieved (all changes year-on-year)
• Strong growth in domestic and overseas sales, combined with a significant increase in other revenue driven by one-time income, and royalty income related to Hemlibra^® and NEMLUVIO^®, resulted in increased revenue and profit year-on-year
• Achieved eight regulatory filings in Japan during the first half of the year, progressing steadily toward achieving the highest number of filings ever planned
• R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects
• For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated
• For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in ALK-positive non-small cell lung cancer expected to start shortly
• For Enspryng^®, developed using Chugai’s proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation
• Regarding products out-licensed to third parties, global market penetration of Chugai-originated new products advanced
• Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth
• As for Foundayo™ (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naïve patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter

Presentation Materials

In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and transcripts (including Q&A) will be made available at a later date.

https://www.chugai-pharm.co.jp/english/media/conference.html

[2026 Second Quarter Results]